Morris Animal Foundation-funded researchers at Texas A&M University and the University of Georgia may have discovered a way to treat deadly foal pneumonia without promoting multi-drug resistant bacteria. In a clinical trial, they found that gallium maltolate (GaM), a semi-metal compound with antimicrobial and anti-inflammatory properties, could be a viable alternative to overprescribed antibiotics. The team published their findings in the Nature journal Scientific Reports.
Pneumonia is one of the leading causes of disease and death in foals and there is currently no effective vaccine licensed. The bacterium Rhodococcus equi (R. equi), a naturally occurring bacterium in soil, is implicated in the most severe cases in horses. Unfortunately, current methods to screen for R. equi are imprecise and many foals are treated with antibiotics, such as the combination of a macrolide antimicrobial (e.g. azithromycin, the antibiotic in the commonly prescribed Z-pack for human use) with rifampin (MaR), even though they would not have developed pneumonia.
“While that treatment strategy saves lives in the short term, it’s really driving this resistance problem because for every one foal that needs treatment, you treat several foals that don’t need treatment,” said Dr. Noah Cohen, the Patsy Link Chair in Equine Research at Texas A&M University, a primary investigator of the study, along with his colleague Steeve Giguère (deceased). “For the sake of foals, we want to offer veterinarians a better, nontraditional option.”
For the study, the team screened 57 foals from four farms in central Kentucky for subclinical pneumonia, then divided the foals into three equal groups. Two groups contained foals with subclinical pneumonia, meaning ultrasounds found lesions on their lungs but the foals had no clinical signs. The foals also all lived on farms with positive cases of R. equi pneumonia that year. Those groups were given either MaR or GaM for two weeks.
The third group served as a control group and was made up of foals that were the same age as the subclinical foals, but were healthy. They were monitored and not given any treatment.
After two weeks, researchers analyzed fecal samples from each foal. DNA tests revealed that the MaR treated group had an increase in both the number and diversity of antibiotic-resistant genes in the bacteria. Most alarming was the discovery that the bacteria were resistant to multiple drugs and antibiotics. The GaM treated and control groups showed no change in the number or diversity of resistance genes, a positive finding.
The team also experimentally infected soil plots with resistant and nonresistant strains of R. equi to see how foals might contaminate their environment with their excrement that can contain unabsorbed and metabolized antibiotics. MaR tended to reduce the number of bacteria in a plot’s soil but increase the proportion that were resistant.
Dr. Cohen said one of his team’s next steps is to test the effectiveness of GaM on foals that are clinically infected with R. equi.
“The widespread use of antibiotics has consequences and we really need to be prudent in prescribing them,” said Dr. Janet Patterson-Kane, Morris Animal Foundation Chief Scientific Officer. “Gallium maltonate may be an excellent alternative and we hope, if proven fully effective, that it could be put into regular use.”
The Foundation also funded a companion paper to this study where researchers compared three techniques to monitor antimicrobial activity and the spread of antimicrobial resistant R. equi.
Morris Animal Foundation, headquartered in Denver, is one of the largest nonprofit animal health research organizations in the world, funding more than $155 million in studies across a broad range of species.
About Morris Animal Foundation
Morris Animal Foundation’s mission is to bridge science and resources to advance the health of animals. Founded by a veterinarian in 1948, we fund and conduct critical health studies for the benefit of all animals. Learn more at morrisanimalfoundation.org.
Public Relations Associate Director